All Companies

Abliva Ab [ABLI:ST] SKr279 MM MCap
Fo­cused on rare and se­vere pri­mary mi­to­chon­drial dis­eas­es (PMD). KL1333, a NAD+ reg­u­la­tor, to ac­cel­er­ate in­to piv­o­tal studies in 2H21 based on pos­i­tive FDA feed­back; ini­tial re­sults from Ph1b in PMD pa­tients exp. in 1Q21. NV354, an en­er­gy re­place­ment ther­a­py for Leigh Syn­drome, in IND-en­abling studies. [more in­for­ma­tion]
Acceleron Pharma Inc [XLRN] $7,708 MM MCap
The com­pa­nies have mul­ti­ple Ph2 and Ph3 trials on­go­ing for chron­ic ane­mia in ad­di­tio­n­al pa­tient pop­u­la­tions of MDS and be­ta-tha­lassemia, as well as myelo­fi­bro­sis. The com­pany ex­pects to re­port to­p­line re­sults from Ph2 clin­i­cal trials in PAH (so­tater­cept) and CMT (ACE-083) in Q1 2020. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] $143 MM MCap
Launched DSU­VIA (sufen­tanil sublin­gual tablet 30 mcg) in the US in 2019 for acute pain se­vere enough to re­quire opi­oid anal­gesic (adult pa­tients in cer­ti­fied med­i­cal­ly su­per­vised health­care sett­ings). Al­so de­vel­op­ing Za­lvi­so (Ph 3 com­plet­ed) in the US as an in­no­va­tive pa­tient-con­trolled anal­ge­sia sys­tem for mod­er­ate-to-se­vere acute pain in med­i­cal­ly su­per­vised sett­ings. [more in­for­ma­tion]
Adrenomed AG
Pre­ci­sion medicine, car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; fi­nal da­ta re­leased late Novem­ber: Ear­ly ap­pli­ca­tion of Adre­cizumab leads to a rapid and sta­tis­ti­cal­ly sig­ni­f­i­cant im­prove­ment of fluid bal­ance, sys­temic or­gan func­tion and > 50% rel­a­tive re­duc­tion of all cause mor­tal­i­ty af­ter 28 days and 90 days com­pared to place­bo on top of SoC. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. Lead can­di­date is an IL-17 with pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis and Ph2 IND for lead in­di­ca­tion uvei­tis will be filed in Q1 2021. In ad­di­tion, the com­pany has an on­go­ing re­la­tion­ship with In­ma­gene in Chi­na. Backed by In­ves­tor AB. [more in­for­ma­tion]
Affimed N.V. [AFMD] $812 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
Aileron Therapeutics, Inc. [ALRN] $94 MM MCap
Clin­i­cal stage on­col­o­gy com­pany con­duct­ing 3 clin­i­cal trials for its lead can­di­date, AL­RN-6924, a first-in-class/best-in-class drug that tar­gets the p53 path­way. AL­RN-6924 is from the Sta­pled pep­tide plat­form and is the on­ly clin­i­cal drug can­di­date that binds equipo­tent­ly to both of the p53 sup­pres­sor pro­teins, MD­MX and MD­M2. [more in­for­ma­tion]
Alladapt Immunotherapeutics, Inc.
[more in­for­ma­tion]
Amarin Corporation [AMRN] $1,674 MM MCap
Com­mer­cial­iz­ing Vas­ce­pa, the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA. First 9mo rev’s of 2020 ~$450M. [more in­for­ma­tion]
Antev
Phase 3 ready, Tevere­lix, a long act­ing in­jectable pep­tide GnRH an­ta­g­on­ist. Lead in­di­ca­tion for pros­tate can­cer, fol­lowed by be­nign pro­stat­ic hy­per­pla­sia (BPH), acute uri­nary re­ten­tion (AUR), uterine fi­broids and en­dometrio­sis. Over 450 sub­jects have been dosed over 850 times to date with no se­ri­ous ad­verse re­ac­tions and good lo­cal tol­er­ance. [more in­for­ma­tion]
Aptorum Group [APM] $91 MM MCap
Ap­to­rum is Hong Kong based, US list­ed com­pany (Mcap $100m) fo­cused on gen­er­at­ing late stage clin­i­cal can­di­dates by de­vel­op­ing al­ready ap­proved drugs for new or­phan in­di­ca­tions, as well as in­fec­tious dis­eas­es. Pipe­line – • SACT-1 for Neu­roblas­to­ma – ph2/3 trial planned for 2H’20 • SACT-COV­19 – COVID-19 treat­ment - pre­clin­i­cal [more in­for­ma­tion]
Arcellx
Clin­i­cal stage de­vel­op­ment of Anti­gen Re­cep­tor Com­plex T-cells (ARC-T) that are read­i­ly si­lenced, ac­ti­vat­ed and re­pro­grammed in vi­vo by ad­min­is­tra­tion of a tu­mor-tar­get­ing anti­gen pro­tein called a sparX. Backed by NEA, No­vo, SR One, Take­da, So­las­ta, Quan, Clough, Mi­rae, JVC and LG. [more in­for­ma­tion]
Ascentage Pharma [6855.HK]
As­cen­t­age Phar­ma has built a pipe­line of eight clin­i­cal drug can­di­dates, in­clud­ing a nov­el, high­ly po­tent Bcl-2/Bcl-xL in­hibi­tor, as well as can­di­dates aimed at IAP and MD­M2-p53 path­ways, and next-gen­er­a­tion ty­ro­sine ki­nase in­hibi­tors. The com­pany has been con­duct­ing 28 Phase I/II clin­i­cal trials to eval­u­ate the eight drug can­di­dates in the Unit­ed States, Aus­tralia, and Chi­na. [more in­for­ma­tion]
AsclepiX Therapeutics
Lead com­pound AX­T107: nov­el pep­tide, in­hibit­ing VEGF and ac­ti­vat­ing Tie2 is the on­ly ther­a­peu­tic in clin­i­cal de­vel­op­ment for DME and wet AMD that was iden­ti­fied through a pro­cess of Ar­ti­fi­cial In­tel­li­gence, min­ing the hu­man pro­teome for cryp­tic an­ti an­gio­genic and home­o­stat­ic pep­tides, rather than through a stan­dard drug de­vel­op­ment pro­cess. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] $139 MM MCap
Tar­get­ing HBV w/ oral core in­hibi­tors - po­ten­tial to in­crease cure rates. Lead can­di­date 731 in Ph 2: +ive safe­ty and de­creas­es in cc­cD­NA pop with pts ex­pect­ed to be with­drawn from treat­ment in 2020 and fol­lowed for sus­tained vi­ral DNA sup­pres­sion off ther­a­py. [more in­for­ma­tion]
Austhera Biosciences
Un­lock­ing the FULL promise of poor­ly ab­sorbed drugs and cre­at­ing nov­el NCEs for on­col­o­gy and rare dis­ease, de­liv­er­ing op­ti­mal ther­a­peu­tic ben­e­fit to pa­tients by max­i­miz­ing drug ex­po­sure. Aus­thera al­so has full rights to use Dis­per­Sol’s Kineti­Sol tech­nol­o­gy plat­form in drug dis­cov­ery to find and de­vel­op in­sol­u­ble new chem­i­cal en­ti­ties (NCEs) of sig­ni­f­i­cant ther­a­peu­tic promise. [more in­for­ma­tion]
AxoGen [AXGN] $828 MM MCap
Ax­o­gen is a pi­oneer in the re­gen­er­a­tive medicine mar­ket, with a prod­uct port­fo­lio for pe­ripher­al nerve re­pair. [more in­for­ma­tion]
Bavarian Nordic A/S [BVNRY] $2,644 MM MCap
Vaccines for in­fec­tious dis­eas­es and on­col­o­gy. [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] $26 MM MCap
Molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­ables phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram: Ph2 for ri­vo-cel (al­pha/be­ta ad­d­back T-cell ther­a­py for post al­lo­gene­ic HSTC in non-ma­lig­nant and ma­lig­nant dis­eas­es). Pos­i­tive late in­ter­im anal­y­sis on ri­vo-cel exp at ASH 2018; [more in­for­ma­tion]
Bellus Health [BLU] $224 MM MCap
BEL­LUS' lead prod­uct can­di­date, BLU-5937, is be­ing de­vel­oped for the treat­ment of chron­ic cough (Phase II an­nounced Ju­ly 2020) and chron­ic pru­ri­tus (Phase II planned to be­gin 1H20). [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr2,166 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] $8,208 MM MCap
NURTEC® ODT ap­proved in 1Q20. NURTEC® ODT for pre­ven­ta­tive treat­ment of mi­graine ap­proved 1Q2021. 4Q21 exp. Ph3 MSA read­out. [more in­for­ma­tion]
BiomX [PHGE] $110 MM MCap
The com­pany's ther­a­peu­tics dis­cov­er and vali­date pro­pri­e­tary bac­te­rial tar­gets, de­vel­op ra­tio­n­al­ly de­signed phage ther­a­pies that seek and de­stroy harm­ful bac­te­ria in mi­cro­biome-re­lat­ed dis­eas­es, en­abling med­i­cal prac­ti­tion­ers to erad­i­cate harm­ful bac­te­ria in chron­ic dis­eas­es. [more in­for­ma­tion]
BioXcel Therapeutics, Inc. [BTAI] $725 MM MCap
BX­CL501 (sublin­gual dexmede­to­mi­dine): Met pri­mary, key se­condary and ex­plo­ra­to­ry end­points in two piv­o­tal Phase 3 trials for the for the acute treat­ment of ag­i­ta­tion in pa­tients with schi­zophre­nia (SERENI­TY I) and bipo­lar di­s­or­der (SERENI­TY II). Phase 1b/2 trial (TRAN­QUIL­I­TY) on­go­ing for the acute treat­ment of ag­i­ta­tion as­so­ci­at­ed with ge­ri­a­tric de­men­tia. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] $165 MM MCap
Co-com­mer­cial as­set CNCT-19/CD19 CAR-T (part­nered w/ Ju­ven­tas): on­go­ing Ph 1 trials in B-NHL and B-ALL, exp to ini­ti­ate reg­is­tra­tion trials by YE 2020. Exp to ini­ti­ate Ph 1 study for CID-103 (an­ti-CD38 mAb) in EU in Q1 2021. [more in­for­ma­tion]
Celularity
Pro­duc­tize al­lo­gene­ic cells and tis­sues de­rived from the post­par­tum pla­cen­ta and have the abil­i­ty to aug­ment im­mu­ni­ty and longevi­ty by am­pli­fy­ing the body's abil­i­ty to fight dis­ease, heal and re­gen­er­ate it­self, en­abling pa­tients to be­gin treat­ment more quick­ly, re­sult­ing in a bet­ter med­i­cal out­come. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
CureVac AG [CVAC] $9,831 MM MCap
Ger­man mR­NA com­pany with a di­ver­si­fied pipe­line; Ph 2a trial on­go­ing with COVID-19 vaccine can­di­date, CVn­CoV. Glob­al Ph 2/3 trial en­rolling ap­prox. 36,500 par­ti­ci­pants with re­sults ex­pect­ed 1Q21. Three other pro­grams in Ph 1: CV8102 (cu­ta­neous me­lano­ma, ade­noid­cys­tic car­ci­no­ma, squa­mous cell can­cer of skin, head & neck), CV9202 (NS­CLC) and CV7202 (Ra­bies). mR­NA-based anti­body de­liv­ery deal with Genmab (Dec'19). Other strate­g­ic part­n­er­ships in­clude GSK and CRIS­PR Tx. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] $653 MM MCap
1Q20 IND sub­mis­sion for lead as­set, EPI-7386, a small molecule tar­get­ing n-ter­mi­nal do­main of an­dro­gen re­cep­tor for mCR­PC. First pa­tient dosed in EPI-7386 Phase 1 study in mCR­PC pa­tients fail­ing se­cond gen­er­a­tion an­tian­dro­gens by 2Q20. [more in­for­ma­tion]
Faraday Pharmaceuticals
Chron­ic and acute agents to pre­vent car­di­ac and skele­tal mus­cle loss by mo­d­u­lat­ing neu­ro­hu­mo­ral path­ways and res­tor­ing metabolic flex­i­bil­i­ty: lead can­di­date FDY-5301 Ph 3 ready for reper­fu­sion in­jury fol­low­ing heart at­tack (AMI). $57M raised to date from Arch Ven­ture Part­n­ers, Po­laris Part­n­ers, WRF, Os­age [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
Galera Therapeutics [GRTX] $221 MM MCap
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cus­ing on trans­form­ing ra­dio­ther­a­py in can­cer. Lead as­set GC4419 is a po­tent, high­ly se­lec­tive small molecule dis­mu­tase mimet­ic be­ing de­vel­oped for se­vere oral mu­cosi­tis, cur­rent­ly in Phase 3 with Break­through Ther­a­py Desig­na­tion. To­p­line re­sults ex­pect­ed in 1H21. Top line re­sults in Phase 1b/2a in se­cond as­set, GC4419 in pan­cre­at­ic can­cer ex­pect­ed in 2H20. GC4419 ex­pect­ed to ini­ti­ate in Phase 1b/2a in lung can­cer in 2H20. [more in­for­ma­tion]
Genfit SA [GNFT] $170 MM MCap
De­vel­op­ment of ela­fi­branor in PBC: on­go­ing en­roll­ment for Ph 3 clin­i­cal trial EL­A­TIVE™. Com­mer­cial­iza­tion of NIS4™ for NASH di­ag­no­sis. [more in­for­ma­tion]
HaemaLogiX
Pro­pri­e­tary, dif­fer­en­ti­at­ed B cell tar­gets en­gaged via anti­body and CAR-T pro­grams Kap­paMab & Lamb­daMab tar­get ac­ti­vat­ed plas­ma cell anti­gens (KMA/LMA); Kap­paMab plus RevDex vs. RevDex Ph 2b in MM, da­ta 1H20; Kap­pa CAR-T Ph 1 Q120 in MM; Ca­pac­i­ty for du­al-tar­get­ing via CD-19, BC­MA, etc; Lamb­daMab in pre­clin­i­cal for amy­loi­do­sis [more in­for­ma­tion]
Hangzhou Chance Pharmaceuticals
Chance fo­cus­es on in­ha­la­tion prod­ucts with pro­pri­e­tary tech­nolo­gies. [more in­for­ma­tion]
Heidelberg Pharma AG [HPHA:DB] €243 MM MCap
Hei­del­berg Phar­ma AG (HPHA, Frank­furt Stock Exchange), based in La­den­burg, Ger­many, is a lead­ing biotech com­pany pi­oneer­ing the use of its AT­AC (Anti­body Tar­get­ed Amanitin Con­ju­gate) plat­form to de­vel­op nov­el can­cer treat­ments with a unique mode of ac­tion ef­fec­tive at spe­cif­i­cal­ly killing both in­ac­tive and di­vid­ing can­cers cells and over­com­ing tu­mor re­sis­tance mech­anisms. [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] $6,299 MM MCap
Chi-Med has a port­fo­lio of 8 drugs in clin­i­cal de­vel­op­ment from own dis­cov­ery en­gine in its In­no­va­tion plat­form and a cash gen­er­at­ing Com­mer­cial plat­form with 2,500+ sales reps. Glob­al col­lab­o­ra­tion with As­traZene­ca in two reg­is­tra­tion en­abling studies with savol­i­tinib in Ta­gris­so re­frac­to­ry lung can­cer that is MET+ and EGFRm+ (glob­al) and MET Ex­on 14 dele­tion NS­CLC (Chi­na). [more in­for­ma­tion]
Immatics NV [IMTX] $766 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Impact Therapeutics Inc
Im­pact Ther­a­peu­tics is a pri­vate­ly held clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany and ded­i­cates to the dis­cov­ery and de­vel­op­ment of tar­get­ed an­ti-can­cer ther­a­peu­tics based on syn­thet­ic lethal­i­ty. [more in­for­ma­tion]
IN8bio, Inc.
IN­8bio is cur­rent­ly con­duct­ing two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials for both of its lead gam­ma-del­ta T cell prod­uct can­di­dates: INB-200 for the treat­ment of new­ly di­ag­nosed glioblas­to­ma, which is a dif­fi­cult to treat brain tu­mor that pro­gress­es rapid­ly, and INB-100 for the treat­ment of pa­tients with acute leukemia un­der­go­ing he­ma­topoi­et­ic stem cell tran­s­plan­ta­tion. [more in­for­ma­tion]
Inozyme Pharma [INZY] $403 MM MCap
Lead can­di­date INZ-701 is an en­zyme re­place­ment ther­a­py de­signed to treat cal­ci­fi­ca­tion di­s­or­ders of the cir­cu­la­to­ry sys­tem, bone and kid­ney for which in­suf­fi­cient treat­ment op­tions cur­rent­ly ex­ist. ENP­P1 and ABC­C6 de­fi­cien­cy Phase 1/2 ini­ti­a­tions ex­pect­ed H1'2021 with re­sults H2'2021. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] $3,442 MM MCap
Late-stage cell ther­a­py com­pany uti­l­iz­ing pro­pri­e­tary au­tol­o­gous tu­mor in­fil­trat­ing lym­pho­cytes (TILs) to at­tack solid tu­mors. The com­pany is con­duct­ing piv­o­tal stage trials in me­tastat­ic me­lano­ma and ad­vanced cer­vi­cal can­cer with BLAs ex­pect­ed 2020. [more in­for­ma­tion]
Junshi Biosciences [1877:HK]
Has a di­ver­si­fied R&D pipe­line com­pris­ing 21 drug can­di­dates with ther­a­peu­tic ar­eas cov­er­ing can­cer, metabolic, au­toim­mune, neu­ro­log­i­cal, and in­fec­tious dis­eas­es. Prod­uct types in­clude mon­o­clo­n­al anti­bodies, fu­sion pro­teins, anti­body-drug con­ju­gates, and small molecule drugs. With a com­bined 33,000L fer­men­ta­tion ca­pac­i­ty in two GMP-fa­cil­i­ties at Shang­hai and Suzhou. JS001, or tori­pal­imab, is ap­proved by the NM­PA and the first mar­ket­ed an­ti-PD-1 mAb anti­body self-de­vel­oped by a PRC com­pany. [more in­for­ma­tion]
KAHR
The com­pany lead prod­uct, DSP107, is a CD47-41BB tar­get­ing com­pound that si­mul­ta­ne­ous­ly tar­get can­cer cells, weak­en their in­nate de­fens­es and ac­ti­vate an ef­fec­tive, lo­cal re­sponse of both in­nate (by block­ing ‘Don’t eat me’ sig­nals) and adap­tive im­mu­ni­ty (by pro­vid­ing co-sti­m­u­la­tion sig­nal to T and NK cells). [more in­for­ma­tion]
Keros Therapeutics [KROS] $869 MM MCap
Our lead pro­tein ther­a­peu­tic prod­uct can­di­date, KER-050, is be­ing de­vel­oped for the treat­ment of cy­tope­nias, in­clud­ing ane­mia and throm­bo­cy­tope­nia, in pa­tients with myelodys­plas­tic syn­drome and myelo­fi­bro­sis. [more in­for­ma­tion]
Kintor Pharma [9939-hk]
Two Ph3s on­go­ing in Chi­na: Piv­o­tal monother­a­py and com­bo with abi­raterone and a Ph2 on­go­ing in US for mCR­PC (with breast and other AR-driv­en can­cers be­hind). Ad­di­tio­n­al pipe­line in­cludes a top­i­cal AR for alope­cia and ear­li­er-stage tar­gets in­clud­ing ALK-1 and hedge­hog. [more in­for­ma­tion]
Landos Biopharma [LABP] $464 MM MCap
Pipe­line tar­gets nov­el im­munometabolic path­ways, in­clud­ing LAN­CL2, NL­RX1 and PLXD­C2. Lead as­set omi­lan­cor is a nov­el, oral, gut-re­strict­ed small molecule ther­a­peu­tic can­di­date for the treat­ment of ul­cer­a­tive coli­tis (com­plet­ed Ph2), Crohn’s dis­ease (Ph2) and Eosinophil­ic Esophagi­tis that tar­gets the LAN­CL2 path­way [more in­for­ma­tion]
LianBio
Lian­Bio col­lab­o­rates with world-class part­n­ers across a di­verse ar­ray of ther­a­peu­tic and ge­o­graph­ic ar­eas to build out a pipe­line based on dis­ease rel­e­vance and the abil­i­ty to im­pact pa­tients with trans­for­ma­tive mech­anisms and pre­ci­sion-based ther­a­peu­tics. [more in­for­ma­tion]
Lineage Cell Therapeutics Inc. [LCTX] $381 MM MCap
Cell ther­a­py com­pany with 3 clin­i­cal pro­grams 1) OpRe­gen, an RPE tran­s­plant ther­a­py in Ph1/2a de­vel­op­ment for the treat­ment of dry-AMD. 2) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py for acute spi­nal cord in­juries with Or­phan and RMAT desig­na­tions. 3) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in a Ph 1 for NS­CLC con­duct­ed by CRUK. [more in­for­ma­tion]
Marker Therapeutics [MRKR] $176 MM MCap
MT-401, its lead Mul­ti­TAA-spe­cif­ic T cell prod­uct can­di­date, has re­ceived Or­phan Drug Desig­na­tion for the treat­ment of post-tran­s­plant acute myeloid leukemia (AML) and is cur­rent­ly in a Phase 2 study (n=160) eval­u­at­ing clin­i­cal ef­fi­ca­cy in both the ad­ju­vant (n=120) and ac­tive dis­ease (n=40) sett­ing. [more in­for­ma­tion]
MiNA Therapeutics
De­vel­op­er of ther­a­peu­tic medicines de­signed to har­ness gene ac­ti­va­tion mech­anisms through small ac­ti­vat­ing RNA. The com­pany's tech­nol­o­gy and clin­i­cal know-how trans­form the ther­a­py land­s­cape of can­cer and other se­vere dis­eas­es, en­abling doc­tors and physi­cians to cure can­cer and other se­vere dis­eas­es and de­vel­op new medicines that re­s­tore nor­mal func­tion to pa­tients' cells. [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $1,023 MM MCap
Next-gen­er­a­tion molec­u­lar glue-based tar­get­ed pro­tein degra­da­tion plat­form de­vel­op­ing small molecule ther­a­peu­tics that se­lec­tive­ly de­grade dis­ease-caus­ing pro­teins. Tar­get­ing the un­drug­gable pro­teome in on­col­o­gy and non-on­col­o­gy in­di­ca­tions via AI based de­gron pre­dic­tion. Ex­ten­sive in vi­vo da­ta to date has de­mon­s­trat­ed po­tent an­ti-tu­mor ac­tiv­i­ty. Lead pro­gram fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of Myc-in­duced trans­la­tio­n­al ad­dic­tion. DC se­lec­tion for lead pro­gram ex­pect­ed in 2021. [more in­for­ma­tion]
NexImmune, Inc. [NEXI] $247 MM MCap
Mul­ti-anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Two Ph 1's on­go­ing. [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
Novavax AB [NVAX] $13,633 MM MCap
A clin­i­cal-stage vaccine com­pany com­mitt­ed to de­liv­er­ing nov­el prod­ucts to pre­vent a broad range of in­fec­tious dis­eas­es. Our re­com­bi­nant nano­par­ti­cles and Ma­trix-M™ ad­ju­vant tech­nol­o­gy are the foun­da­tion for ground­break­ing in­no­va­tion that im­proves glob­al health through safe and ef­fec­tive vaccines. [more in­for­ma­tion]
OncoResponse
The com­pany's tech­nol­o­gy lev­er­ages the hu­man im­mune sys­tem to iden­ti­fy ful­ly hu­man mon­o­clo­n­al anti­bodies and dis­cov­er nov­el tar­gets that will lead to the de­vel­op­ment of anti­body-de­rived ther­a­peu­tics for the treat­ment of can­cer, pro­vid­ing a larg­er num­ber of can­cer pa­tients with the ben­e­fit of im­munother­a­py. [more in­for­ma­tion]
Oncorus [ONCR] $321 MM MCap
The com­pany's lead pro­gram ON­CR-177 is a Ph1 oHSV with com­ple­men­tary pay­loads (PD1, CCL4, IL12, FLT3, CT­LA4) to en­cour­age im­mune sti­m­u­la­tion, with read­out guid­ed for 2H21. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr3,507 MM MCap
Rev­enue-gen­er­at­ing urol­o­gy-fo­cused com­pany. Lead prod­uct, Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC), which can re­duce dis­ease re­cur­rence and pro­gres­sion rates. Hexvix®/Cysview® is in­clud­ed in clin­i­cal consen­sus guide­lines and re­mains on a strong growth path. Rev­enues in 2020 to­taled $31M. Re­cent­ly suc­cess­ful­ly launched the Eu­ro­pean Hexvix op­er­a­tions, con­soli­dat­ing the Com­pany’s prod­uct franchise glob­al­ly. Pho­to­cure is head­quar­tered in Os­lo, Nor­way and list­ed on [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] $199 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] $2,236 MM MCap
Pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op oral tar­get­ed ther­a­py-based drugs and in­jecta­bles for rare dis­eas­es. PTG-300 in­jectable hep­cidin mimet­ic Ph 2 trials on­go­ing in po­ly­cythemia ve­ra and hered­i­tary he­mochro­ma­to­sis; pos­i­tive up­dat­ed Ph 2 re­sults in PV pre­sent­ed at ASH 2020. PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis study sites ac­ti­vat­ed; PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist Ph 2 Crohn’s dis­ease study on­go­ing. [more in­for­ma­tion]
R2 Technologies
Head­quar­tered in Sil­i­con Val­ley, R2 fo­cus­es on the de­vel­op­ment and com­mer­cial­iza­tion of ground­break­ing tech­nolo­gies for aes­thet­ic providers and con­sumers. Based on the li­censed ex­clu­sive in­tel­lec­tu­al prop­er­ty from Mas­sachusetts Gen­er­al Hos­pi­tal to mo­d­u­late me­lanin pro­duc­tion, R2 Tech­nolo­gies was found­ed in 2014 by Pansend Life Sci­ences and Blos­som In­no­va­tions. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
Po­ten­tial first in class CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors in Ph1b in AML and high-risk MDS, PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni). Da­ta pre­sent­ed in 2020. Ear­ly stage pipe­line ad­dress­ing emerg­ing solid tu­mor tar­gets. [more in­for­ma­tion]
Savara Inc. [SVRA] $146 MM MCap
Or­phan lung dis­ease Com­pany; Mol­gradex, is an in­haled gran­u­lo­cyte-macrophage colony-sti­m­u­lat­ing fac­tor (GM-CSF) in Phase 3 de­vel­op­ment for au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP); study ex­pect­ed to start Q1 2021. Al­so, Phase 3 trial, AVAIL, is eval­u­at­ing per­sis­tent me­thi­cillin-re­sis­tant Sta­phy­lo­coc­cus au­reus (MR­SA) lung in­fec­tion in peo­ple liv­ing with cys­tic fi­bro­sis. Top line da­ta are ex­pect­ed ear­ly in 2021 [more in­for­ma­tion]
Secarna Pharmaceuticals GmbH
Se­car­na's unique­ly ef­fi­cient LNA­plus™ dis­cov­ery pro­cess is fu­eled by their pro­pri­e­tary and stream­lined Oli­go­fy­er™ bioin­for­mat­ics sys­tems large in-house cell li­brary and own in vit­ro screen­ing as­says. [more in­for­ma­tion]
Sigilon Therapeutics, Inc. [SGTX] $167 MM MCap
5 INDs exp in the next 2 years; 1st IND in Jan 2020 (He­mophilia A). Eli Lil­ly col­lab­o­ra­tion in T1D ($75m ini­tial com­mit­ment, $410 mile­s­tones & sin­gle to dou­ble dig­it roy­al­ties). En­gi­neer­ing cells to pro­duce cru­cial pro­teins/en­zymes/etc; en­cap­su­late cells in al­gi­nate sphere co­va­lent­ly bond­ed w/coat­ing that pre­vents fi­bro­sis & re­jec­tion; [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc. [SONN] $24 MM MCap
Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. The Son­net plat­form de-risks the use of in­ter­leukins by great­ly ex­tend­ing their in vi­vo half-life, while al­so im­prov­ing their spe­ci­fic­i­ty to tu­mor tis­sue. [more in­for­ma­tion]
Spruce Biosciences [SPRB] $222 MM MCap
The com­pany’s lead prod­uct can­di­date, til­dac­er­font, is an in­vesti­ga­tio­n­al oral drug that is be­ing eval­u­at­ed in studies for the treat­ment of con­geni­tal adre­nal hy­per­pla­sia (CAH). The com­pany al­so plans to eval­u­ate til­dac­er­font in other dis­eas­es im­pact­ed by el­e­vat­ed ACTH or adre­nal an­dro­gens. [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] $168 MM MCap
Rare dis­eas­es; Keveyis for PPP revs ~21.7M for 2019 and $26 - $27M for 2020. Re­cor­lev for en­doge­nous Cush­ing's syn­drome Ph 3 pub­lished with to­p­line place­bo-con­trolled Ph 3 3Q20. [more in­for­ma­tion]
Sutro Biopharma [STRO] $810 MM MCap
FolR&al­pha;-tar­get­ing ADC (STRO-002) Phase 1, ad­di­tio­n­al dose es­ca­la­tion da­ta in 4Q20. CD74-tar­get­ing ADC (STRO-001) Phase 1, ad­di­tio­n­al dose es­ca­la­tion da­ta in 4Q20. BMS col­lab­o­ra­tion Phase 1 clin­i­cal de­vel­op­ment up­date for CC-99712 (BC­MA-tar­get­ing ADC). Mer­ck col­lab­o­ra­tion up­date in 2020 on first cy­tokine deri­va­tive pro­gram. [more in­for­ma­tion]
Syneos Health [SYNH] $9,213 MM MCap
Sy­neos Health® is an end-to-end, ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions com­pany that works dif­fer­ent­ly. At Sy­neos Health, all the dis­ci­p­lines in­volved in bring­ing new ther­a­pies to mar­ket, from clin­i­cal to com­mer­cial, work to­gether to cre­ate cus­tomer suc­cess. Our unique Bio­phar­ma­ceu­ti­cal Ac­cel­er­a­tion Mod­el de­liv­ers val­ue across the small to mid-size to large cus­tomer cont­in­u­um. [more in­for­ma­tion]
Tessa Therapeutics
On­go­ing Ph III (na­sopha­ryn­geal can­cer), up­com­ing piv­o­tal Ph II (Hodgkin lym­pho­ma), and mul­ti­ple other clin­i­cal-stage pro­grams. GMP fa­cil­i­ty un­der con­struc­tion. Key col­lab­o­ra­tions: Bay­lor, Park­er Inst., St. Jude Chil­dren’s, and JV in Chi­na. [more in­for­ma­tion]
Treos Bio Limited
A pri­vate, clin­i­cal stage com­pany fo­cused on pep­tide can­cer im­munother­a­pies com­pu­ta­tio­n­al­ly matched to pa­tient ge­net­ics/im­mune re­sponse ca­pa­bil­i­ty with­out need for tu­mor biop­sy. Pipe­line in­cludes per­so­n­al­ized + off-the-shelf ther­a­pies for mul­ti­ple solid can­cers and an IND-ready 2nd gen­er­a­tion COVID T-cell vaccine. [more in­for­ma­tion]
Vaccitech Limited [VACC] $498 MM MCap
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces and main­tains CD8+ T-cells at the max­i­mum lev­els pub­lished to date. Ph1/2 da­ta for HPV and HBV im­munother­a­pies ex­pect­ed 2H20. En­cour­ag­ing pros­tate can­cer, 5T4 im­munother­a­peu­tic da­ta re­cent­ly re­leased. Ph1/2 NS­CLC MAGE-NYE­SO im­munother­a­peu­tic en­ters clin­ic in Q1 2021. ChA­dOx COVID-19 vaccine out-li­censed to Ox­ford Uni/As­traZene­ca with post-pan­dem­ic rev­enue stream. $150M fund­ing at Jen­n­er In­sti­tute and com­pany raised $48M since for­ma­tion [more in­for­ma­tion]
Verrica Pharmaceuticals [VRCA] $307 MM MCap
Ver­ri­ca Phar­ma­ceu­ti­cals is a der­ma­tol­o­gy ther­a­peu­tics com­pany de­vel­op­ing med­i­ca­tions for vi­ral skin dis­eas­es re­quir­ing med­i­cal at­ten­tion. Lead prod­uct, VP-102 for mol­lus­cum con­ta­gio­sum has a PD­U­FA date of Ju­ly 13, 2020. Phase 2 da­ta in ex­ter­nal geni­tal warts ex­pect­ed in 2H20. Ini­ti­a­tion of Phase 3 in com­mon warts in 1H20 and ini­ti­a­tion of Phase 2 in plan­tar warts in mid-2020. [more in­for­ma­tion]
Viela Bio [VIE] $2,913 MM MCap
UPLIN­ZA® (ine­bi­l­izumab, an­ti-CD19 mAb) on the mar­ket for the treat­ment of neu­romyeli­tis op­ti­ca spec­trum di­s­or­der (NMOSD). Ad­di­tio­n­al trials with ine­bi­l­izumab on­go­ing, in­clud­ing Ph 3 trials in myas­the­nia gravis and Ig­G4-re­lat­ed dis­ease. VIB7734, an­ti-ILT7 mAb, Ph 2 trial to ini­ti­ate in 1H21. Ph 2 trials on­go­ing for VIB4920 (An­ti-CD40L-Tn3 Fu­sion Pro­tein) in Sjo­gren's Syn­drome and kid­ney tran­s­plant re­jec­tion. [more in­for­ma­tion]
Vivoryon [VVY]
Vivo­ry­on Ther­a­peu­tics is fo­cused on nov­el small molecule in­hibi­tors of glu­taminyl cy­clase (QPCT) de­signed to pre­vent the for­ma­tion of patho­log­i­cal­ly al­tered pro­teins be­fore they cause ir­re­v­ersi­ble da­m­age. Lead can­di­date varog­lu­tam­s­tat, cur­rent­ly in Phase 2 in Alzheimer’s dis­ease (AD), tar­gets all three ma­jor hall­marks of AD. [more in­for­ma­tion]
Werewolf Therapeutics [HOWL] $520 MM MCap
Were­wolf Ther­a­peu­tics, Inc. is an in­no­va­tive bio­phar­ma­ceu­ti­cal com­pany pi­oneer­ing the de­vel­op­ment of ther­a­peu­tics en­gi­neered to sti­m­u­late the body’s im­mune sys­tem for the treat­ment of can­cer. [more in­for­ma­tion]
XOMA Corporation [XOMA] $363 MM MCap
Biotech roy­al­ty and mile­s­tone ag­gre­ga­tor with port­fo­lio of 70+ as­sets in >30 dis­closed in­di­ca­tions where R&D costs are borne by part­n­ers e.g. No­var­tis’s Is­cal­imab (CFZ533) an­ti-CD40 mAb in Ph2. [more in­for­ma­tion]
Zentalis [ZNTL] $2,418 MM MCap
Dis­cov­er­ing and de­vel­op­ing small molecule ther­a­peu­tics tar­get­ing fun­da­men­tal bi­o­log­i­cal path­ways of can­cers. Broad pipe­line of po­ten­tial­ly best-in-class on­col­o­gy can­di­dates, in­clud­ing ZN-c5, an oral se­lec­tive es­tro­gen re­cep­tor de­grad­er for ER+/HER2- breast can­cer, ZN-c3, a WEE1 in­hibi­tor, ZN-d5, a BCL-2 in­hibi­tor and ZN-e4, an EGFR in­hibi­tor. [more in­for­ma­tion]